Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nasus Pharma Ltd. (NSRX)
USD3.00
-0.05 (-1.64%)
IL AMEX Healthcare Medical - Pharmaceuticals
Address
Yigal Alon 65 6744317
Tel Aviv, MA, IL
Tel Aviv, MA, IL
CEO
Dan Teleman
Website
nasuspharma.com
IPO
2025-08-13
CIK 2029039 ISIN IL0012181553
Description
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.00
-0.05 (-1.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
70.9K
Beta
3.93
Float Shares
2.86M
Free Float %
33.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.32% | +6.97% | +12.04% | +14.98% | -59.50% | -66.45% | -62.79% | -62.79% | -62.79% | -62.79% | -62.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
3.00
Low
22.00
+633.3%
Consensus
22.00
+633.3%
Median
22.00
+633.3%
High
22.00
+633.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
22.00
+633.3%
|
| All Time | 1 |
22.00
+633.3%
|
Quality scores
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%-41.7%
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%—
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0%
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×—
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
2
Beneficial owners (>5%)
6
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Udi Gilboa | 1.90M | 21.10% | — | — | — | — | IN | ISRAEL | 2025-11-10 | ↗ |
| 2 | Dr. Dalia Megiddo | 1.89M | 20.90% | — | — | — | — | IN | ISRAEL | 2025-11-12 | ↗ |
| 3 | Dr. Ronnie Hershman | 1.38M | 15.30% | 429.3K | 429.3K | 429.3K | — | IN | UNITED STATES | 2025-11-13 | ↗ |
| 4 | Balyasny Asset Management L.P. | 1.17M | 9.99% | — | — | — | — | IA, PN | DELAWARE | 2026-05-15 | ↗ |
| 5 | Funicular Funds, LP | 612.9K | 5.20% | — | — | — | — | PN | DELAWARE | 2026-04-07 | ↗ |
| 6 | Capital Point Ltd. | 575.1K | 6.35% | — | — | — | — | CO | ISRAEL | 2025-08-20 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
2.9K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+2,900
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | Rubin Eyal | Officer | — | — | Share options (right to buy) | 40,549 | 7.56 | 306.6K | 0 | D | ↗ |
| 2026-04-22 | Teleman Dan Benjamin | Director / Officer | P-Purchase | A | Ordinary Shares | 2,900 | 3.76 | 10.9K | 156,991 | D | ↗ |
| 2026-03-31 | Teleman Dan Benjamin | Director / Officer | P-Purchase | A | Ordinary Shares | 15,000 | 2.04 | 30.6K | 21,246 | D | ↗ |
| 2026-03-18 | Teleman Dan Benjamin | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 6,246 | D | ↗ |
| 2026-03-18 | Megiddo Dalia | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 5,195 | I | ↗ |
| 2026-03-18 | Hershman Ronnie | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 909,156 | I | ↗ |
| 2026-03-18 | Gilboa Udi | Other | — | — | Ordinary Shares | 0 | 0.00 | — | 1,919,281 | D | ↗ |
| 2026-03-11 | Silberman David | Director | — | — | Share Option (right to buy) | 10,000 | 5.38 | 53.8K | 0 | D | ↗ |
| 2026-03-11 | Shacham Sharon | Director | — | — | Share Option (right to buy) | 10,000 | 5.38 | 53.8K | 0 | D | ↗ |
| 2026-03-11 | Israel Isaac | Director | — | — | Share Option (right to buy) | 10,000 | 5.38 | 53.8K | 0 | D | ↗ |
| 2026-02-13 | Hershman Ronnie | Director | — | — | Warrants | 17,970 | 6.53 | 117.3K | 0 | I | ↗ |
| 2026-02-13 | Gilboa Udi | Other | — | — | Warrants | 17,970 | 6.53 | 117.3K | 0 | D | ↗ |
| 2026-01-07 | Teleman Dan Benjamin | Director / Officer | — | — | Share option (right to buy) | 318,856 | 6.05 | 1.93M | 0 | D | ↗ |
| 2020-05-06 | Hershman Ronnie | Director | — | — | Share options (right to buy) | 63,017 | 4.30 | 270.8K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
8.61M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ehud Moshe Gilboa | Co-Founder & Executive Chairman | 545.1K | male |
| Dalia Megiddo | Co-Founder, Director, Chief Medical Officer & Chief Development Officer? | 488.3K | — |
| Dan Teleman | Chief Executive Officer & Director | 295.0K | male |
| Eyal Rubin | CFO & Executive VP | 42.5K | male |
| Galia Temtsin Kryaz | Director of CMC & Product Development | — | — |
| Yifat Bar | Vice President of Administration & Human Resources | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NSRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
